Primary Resistance to RET Inhibition in a RET Fusion-Positive Pancreatic Neuroendocrine Carcinoma
The Oncologist · 2025
DOI: 10.1093/oncolo/oyae034 ↗At a glance
Fallbericht in The Oncologist, 2025. Written by Blake J McKinley and 2 co-authors. Institution: Department of Internal Medicine, Mayo Clinic, Jacksonville, FL, USA. Major MEDLINE topics: Proto-Oncogene Proteins c-ret, Carcinoma, Neuroendocrine, Pancreatic Neoplasms, Drug Resistance, Neoplasm. Cited 4 times so far (Crossref); 23 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
We present a 54-year-old White male with a diagnosis of stage IV pancreatic neuroendocrine carcinoma. Next-generation sequencing of the tumor/blood identified a complex tumor genome, which included a rearranged during transfection (RET) gene fusion. The patient initially received cytotoxic chemotherapy with a significant radiographic response. After 4 cycles of chemotherapy, the patient was transitioned to a clinical trial using selpercatinib, a RET inhibitor, as maintenance therapy. Unfortunately, our patient developed progression of disease at the first treatment monitoring scan. Our patient suffered primary resistance to RET-targeted therapy. Proposed mechanisms of resistance include intrinsic resistance of the nuclear receptor co-activator 4-RET fusion to RET inhibition, the RET fusion representing a passenger alteration to another tumorigenic driver pathway and/or decreased efficacy of RET inhibition after platinum-based chemotherapy. Our patient’s clinical course highlights the fact that “actionable” genomic alterations do not always equate to patient benefit.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Internal Medicine, Mayo Clinic, Jacksonville, FL, USA.
- Division of Medical Oncology, Duke, Raleigh, NC, USA.
- Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL, USA.
ORCID profiles: Blake J McKinley, Jason S Starr
Cite
APA
McKinley, B. J., Coston, T. W., & Starr, J. S. (2025). Primary Resistance to RET Inhibition in a RET Fusion-Positive Pancreatic Neuroendocrine Carcinoma. The Oncologist. https://doi.org/10.1093/oncolo/oyae034
Vancouver
McKinley BJ, Coston TW, Starr JS. Primary Resistance to RET Inhibition in a RET Fusion-Positive Pancreatic Neuroendocrine Carcinoma. The Oncologist. 2025. doi:10.1093/oncolo/oyae034
BibTeX
@article{McKinley2025,
author = {McKinley, Blake J and Coston, Tucker W and Starr, Jason S},
title = {Primary Resistance to RET Inhibition in a RET Fusion-Positive Pancreatic Neuroendocrine Carcinoma},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyae034}
}
EUVIMED